tbuckley/cabot-search huggingface dataset:
FRI0125 Development of Neurological Complications After Therapy with Anti-TNF Drugs: Table 1
Authors: N. Errazquin, C. Meneses, M. Uriarte, C.A. Egües, J. Belzunegui
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> According to prospectus, cautious evaluation concerning potential risk of developing demyelinating diseases in patients treated with anti-TNF drugs should be considered before initiating therapy. There are several case reports of neurological complications in patients treated with anti-TNF drugs. The annual rate of this complications according with the Spanish Registry BIOBADASER in 2011, was 0.65/1000 patient-years (IC95 0.36-1.1) [1]. Until now, there is no cause-effect relationship known. <h3>Objectives</h3> To describe the demographic characteristics, underlying disease and anti-TNF drug used in patients who developed neurological complications in the period 2000 – 2014 in the Rheumatology Department of the Donostia University Hospital, Spain. <h3>Methods</h3> We retrospectively identified patients who were administered anti-TNF drugs and subsequently developed neurological deficits. The analyzed variables were sex, age, underlying disease, anti-TNF drug, cumulative dose, complications, treatment and clinical outcome. The prevalence of these complications was measured. <h3>Results</h3> We registered 388 patients treated with Infliximab (IFX), 39 with Adalimumab (ADA), 351 with Golimumab (GLM), 33 with Certolizumab (CZP) and 375 with Etanercept (ETN). A total of 7 cases (5 women and 2 men) were found with a median age of 48 years old, of whom 4 were diagnosed of rheumatoid arthritis (RA), 3 of spondyloarthritis (SA) and 1 of uveitis of unknown etiology. The anti-TNF drug found to be more associated with neurological complications was Infliximab (5 cases). The neurological complications included: posterior demyelinating optic neuritis (PDON), demyelinating motor polyneuropathy (DMPN) and "Stiff-man Syndrome" (SMS) with positive anti-glutamic acid decarboxylase (GAD) antibodies. The analized variables are shown in the table. The registered prevalence in our study was 0.6%. <h3>Conclusions</h3> All neurological complications developed after the use of monoclonal antibodies, being IFX responsible for 71% of cases. The cumulative drug dosage with IFX was very variable amongst patients, therefore complications do not seem to be directly related to the dose. <h3>References</h3> C. Rodríguez Lozano. Seguridad de las terapias biolόgicas: nuevos datos de BIOBADASER. Reumatol Clin. 2011;6(S3):S1–S6. <h3>Disclosure of Interest</h3> None declared
Blood Uric Acid and Proteose, Body Temperature, and Glomerular Clearance of Rabbits Implanted with The Brown-Pearce Carcinoma and Treated with The Polysaccharide from Serratia Marcescens
Authors: Westfall, Benton B., Dunn, Thelma B.
Journal: JNCI Journal of the National Cancer Institute (1946)

Journal Article Blood Uric Acid and Proteose, Body Temperature, and Glomerular Clearance of Rabbits Implanted with The Brown-Pearce Carcinoma and Treated with The Polysaccharide from Serratia Marcescens Get access Benton B. Westfall, Benton B. Westfall biochemist National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar Thelma B. Dunn Thelma B. Dunn research fellow in pathology National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 7, Issue 3, December 1946, Pages 115–121, https://doi.org/10.1093/jnci/7.3.115 Published: 01 December 1946 Article history Received: 30 July 1946 Published: 01 December 1946
Proliferative Changes Induced in the Vaginae of Intact Strain BALB/c Mice with Croton Oil, Olive Oil, and Methylcholanthrene&lt;xref ref-type="fn" rid="fn1"&gt;2&lt;/xref&gt;,&lt;xref ref-type="fn" rid="fn2"&gt;3&lt;/xref&gt;
Authors: Michael Klein
Journal: JNCI Journal of the National Cancer Institute (1955)

Journal Article Proliferative Changes Induced in the Vaginae of Intact Strain BALB/c Mice with Croton Oil, Olive Oil, and Methylcholanthrene, Get access Michael Klein Michael Klein Cancer Research Laboratory, University of Florida, Gainesville, Fla. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 16, Issue 1, August 1955, Pages 255–265, https://doi.org/10.1093/jnci/16.1.255 Published: 01 August 1955 Article history Received: 02 December 1954 Published: 01 August 1955
Abstract 4303: Programmed death ligand 1 (PD-L1) expression in paired melanoma tumor samples
Authors: Torben Steiniche, Allan Vestergaard Danielsen, Zhen (Adelle) Wang, Patricia Switten Nielsen, Lars Bastholt, Henrik Schmidt, Inge Marie Svane, Marisa Dolled-Filhart, Kenneth Emancipator, Dianna Y. Wu, Michael Busch-Sorensen, Wei Zhou
Journal: Cancer Research (2015)

Abstract Background: There is limited information on changes in PD-L1 expression levels over time in melanoma. Methods: PD-L1 expression was measured in melanoma tumor samples collected at different time points from the same patient using a prototype immunohistochemistry (IHC) assay with the 22C3 antibody. PD-L1 positivity was defined as staining in ≥1% of cells. The concordance of PD-L1 expression in paired samples was analyzed by treating the IHC proportion score as a continuous variable or classifying staining as positive or negative. Results: 48 patients were included. Median age was 65 years (range, 23-85), 73% were male, and 60% had stage I-IIIA disease. All first samples and 85% of second samples were surgical samples. The median interval between sample collection dates was 25.3 months (range, 3.1-203.5). There was no statistically significant correlation of the PD-L1 IHC proportional score between paired samples (Pearson correlation coefficient, 0.13). 40% of patients had an increased proportion score at the second time point, and 10% had a decreased score. The prevalence of PD-L1 positivity was 31% in first samples and 46% in second samples. The concordance rate was 65% (95% CI, 49%-78%) when PD-L1 expression was categorized as positive or negative (Table). The concordance rate was similar in paired samples collected within and beyond 2 years. Concordance of PD-L1 Expression in Paired Melanoma Samples (N = 48)Later Time PointPD-L1 ExpressionPositive, n (%)Negative, n (%)Earlier Time PointPositive10 (20.8)5 (10.4)Negative12 (25.0)21 (43.7) Conclusion: Our preliminary analysis did not suggest a significant correlation of PD-L1 expression in paired melanoma samples collected at different time points. Similar results were observed when samples were categorized as PD-L1 positive or PD-L1 negative. The 35% discordance rate between initial and subsequent tumor samples should be considered if PD-L1 expression is used for selection of enrollment in clinical trials. Citation Format: Torben Steiniche, Allan Vestergaard Danielsen, Zhen (Adelle) Wang, Patricia Switten Nielsen, Lars Bastholt, Henrik Schmidt, Inge Marie Svane, Marisa Dolled-Filhart, Kenneth Emancipator, Dianna Y. Wu, Michael Busch-Sorensen, Wei Zhou. Programmed death ligand 1 (PD-L1) expression in paired melanoma tumor samples. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 4303. doi:10.1158/1538-7445.AM2015-4303
Safety and efficacy of eltrombopag (EPAG) vs placebo (PBO) for treatment of chemotherapy (CTx)-induced thrombocytopenia (TCP) in patients (Pts) with solid tumors receiving gemcitabine (GEM)-based CTx: A phase 2 study.
Authors: Eric S. Winer, Howard Safran, Frederic Forget, Boguslawa Karaszewska, Sebastian Bauer, Dilawar Khan, Brendan Mark Johnson, Paul M. Burgess, Denise C. Althouse, Geoffrey Chan, Yasser Mostafa Kamel
Journal: Journal of Clinical Oncology (2015)

9602 Background: A phase 1 EPAG study showed favorable results for the treatment of CTx-induced TCP in pts receiving GEM-based CTx. Methods: This was a phase 2, blinded, PBO-controlled, multicenter study in adults with solid tumors and TCP receiving ≤6 cycles of CTx. Pts received GEM on days 1 and 8 (every 21 days) and cisplatin on day 1 (or divided dose on days 1 and 8) or carboplatin on day 1, or received GEM alone on days 1, 8, and 15 (every 28 days). Pts were randomized (2:1) to EPAG 100 mg or PBO daily for 5 days before and after day 1 of CTx. Results: We report early results of 44 pts randomized to EPAG (n = 31) or PBO (n = 13). Data review with an external, independent physician after ≥ 2 cycles showed no safety concerns. Myelosuppression was the most common adverse event (AE), with lower rates of anemia, neutropenia, and TCP seen with EPAG versus PBO (Table). In the EPAG arm, 23% of patients developed TCP (all grade 3/4) vs 46% (31% grade 3/4) of PBO patients. Proportionately fewer serious AEs (SAEs)/deaths occurred with EPAG than with PBO. CTx dose delays/reductions for any reason, specifically for TCP, were lower for EPAG pts than PBO pts, with a greater difference shown in later treatment cycles. Conclusions: These early safety and efficacy results are encouraging, with a potential trilineage benefit as seen in other EPAG studies. Enrollment was completed in 2014, with a total of 75 pts. Study NCT01147809 was funded by GlaxoSmithKline. Clinical trial information: NCT01147809. EPAG (n = 31) PBO (n = 13) Any AEs (all grades) on therapy +30 daysa 26 (84) 13 (100) Blood/lymphatic system disorders 20 (65) 10 (77) Thrombocytopenia 7 (23) 6 (46) Anemia 11 (35) 7 (54) Neutropenia 10 (32) 6 (46) Gastrointestinal disorders 14 (45) 7 (54) Blood creatinine increased 2 (6) 2 (15) Vascular disorders 3 (10) 2 (15) Deep vein thrombosis 2 (6) 0 Thrombophlebitis 0 1 (8) Cardiac disorders 1 (3) 0 Myocardial infarction 1 (3) 0 SAEs 9 (29) 7 (54) Deaths 5 (16) 4 (31) CTx dose delays/reductions due to TCP (intent-to-treat population) Cycles 1–6 11/28 (39) 7/13 (54) Cycles 2–6 7/19 (37) 5/10 (50) Cycles 3–6 5/17 (29) 5/8 (63) Data are shown as n (%) or n/N (%). aPts could have >1 AE.
Bone Scan in Iliotibial Band Syndrome
Authors: FRANK DE GEETER, JAN DE NEVE, HILDE VAN STEELANDT
Journal: Clinical Nuclear Medicine (1995)

Iliotibial band syndrome typically occurs in sportsmen. While exercising, especially running or cycling, patients experience progressive pain on the lateral side of the knee. This pain is caused by friction of the iliotibial band against the lateral epicondyle of the femur. The authors report the findings of bone scintigraphy in a patient with this syndrome. A hot spot was present on the posterolateral aspect of the lateral femoral epicondyle. This finding probably resulted from rubbing of the iliotibial band over the bony surface.
PWE-032 Hemospray for acute upper gastrointestinal bleeding – a single centre experience
Authors: MM Widlak, H Wijesinghe, K Siau, T Molitor, MN Quraishi, M Armstrong, T Troth, T Iqbal, J Goh
Journal: Gut (2015)

<h3>Introduction</h3> Upper gastrointestinal bleeding (UGIB) is the commonest medical emergency managed by the Gastroenterologists. Despite of familiarisation with a variety of medical and endoscopic strategies to treat underlying aetiologies, rebleeding and mortality rates remain high. A novel agent, known commercially as Hemospray, has recently been licensed for use in non-variceal upper gastrointestinal bleeding (NVUGIB). <h3>Method</h3> The aim of this study was to assess the effectiveness of Hemospray therapy, either as primary endotherapy, or as part of salvage endotherapy in NVUGIB, when conventional measures to achieve haemostasis were deemed insufficient. All patients treated with Hemospray at University Hospital Birmingham, since its introduction to the Unit in 2013, were retrospectively identified using the Unisoft endoscopy database. Data on the indications for Hemospray use, and application in conjunction with other therapeutic modalities were collected. Outcomes including mortality, primary haemostasis and re bleeding rates were analysed. <h3>Results</h3> Hemospray was applied in 48 patients with NVUGIB (median age 63 years, 70% male). Four patients had Hemospray used on more than one occasion. Causes of bleeding included peptic ulcer disease 29/48 patients (60.5%), other non variceal upper GI pathology 13/48 (27%) and post variceal banding oesophageal ulcers 6/48 (12.5%). Hemospray was used as primary endotherapy in 42/48 patients (87.5%), achieving initial haemostasis in 40/42 cases (95%). 6/48 patients (12.5%) received Hemospray as salvage therapy following a rebleed after treatment with standard primary therapy. Rebleeding within 7 days occurred in 4/42 patients (9.5%); two of them received Hemospray as monotherapy. 30-day mortality in this patient cohort was 9/48 (19%). There were no documented complications of Hemospray therapy. <h3>Conclusion</h3> Hemospray is a safe and effective endoscopic therapy in achieving initial haemostasis, both as primary and salvage therapy, and either as monotherapy or in combination with other endoscopic modalities in a wide variety of upper GI pathologies, including post variceal banding oesophageal ulcers. We have found this to be a useful adjunct in the management of NVUGIB when conventional techniques have failed. However, further studies are needed to define its cost-effectiveness in the acute hospital setting. <h3>Disclosure of interest</h3> None Declared.
Comparative Chromosomal Studies on Mammalian Cells in Culture. II. Mouse Sarcoma-Producing Cell Strains and Their Derivatives&lt;xref ref-type="fn" rid="FN1"&gt;2&lt;/xref&gt;
Authors: Ernest H. Y. Chu, Katherine K. Sanford, Wilton R. Earle
Journal: JNCI Journal of the National Cancer Institute (1958)

Comparative cytological studies were made of mouse sarcoma-producing cell lines maintained in different media, their clonal derivatives, and the sarcomas produced by injection of these lines into mice of the original strain. These sublines were derived from one cell cultured from a cell strain that originated in the normal tissue of a mouse, but differences in morphology, metabolism, and in the frequency with which they produce sarcomas were demonstrated. Mitotic rate comparisons showed that all cell lines exhibited similar mitotic activities in vitro. In addition, mitotic abnormalities were observed in all lines. These lines may be classified as hyperdiploids, with most lines exhibiting characteristic modal chromosome numbers. Variable proportions of higher polyploid cells were found in all lines. Metacentric chromosomes are present in all lines, ranging on the average from 2 to 11 per cell in each line. Furthermore, certain characteristic marker chromosomes can be identified in individual lines. These can be detected in related strains and in the resulting sarcomas. These cell strains clearly have altered chromosome number and morphology as compared with normal mouse cells. Although these studies have established certain characteristic chromosomal differences between the high and low sarcoma-producing lines, there is no present evidence that these differences are directly responsible for their distinctive physiological properties.
SP0072 More or Less – or is Less More
Authors: M. Schneider
Journal: Annals of the Rheumatic Diseases (2015)

Glucocorticoid (GC) therapy is very important in treating lupus patients. There is no other medication for systemic lupus erythematosus (SLE) to which response is comparable fast, and nearly all SLE manifestations seem to respond at least in some part to GC. Therefore GCs are regularly used in about two out of three SLE patients, and GCs are included in any management guideline for SLE. GCs are the initial medication in lupus flares and are therefore used in nearly all trials as induction therapy and tapered afterwards without a harmonized tapering strategy. No recommendation indicates clearly who and when to stop GC in SLE and attempts to evaluate the stopping of GC use do not find their patients and not supported by most physicians. Most physicians, at least in Germany, believe that SLE patients can to survive without GC therapy. Over the last decade increasing evidence was collected that GCs independently of the classical acute and chronic side effects harm SLE patients. Mayor problems are infections and accelerated arteriosclerosis. Guidelines like the Eular recommendations advise the use of immunosuppressive medications like azathioprine, mycophenolate and methotrexate as GC sparing agents, although trials to support this concept are limited. But the number of RCTs that foster the use GCs in SLE is also rare, mostly caused by widespread use of GCs and the long history of clinical success with GCs. From the clinical perspective, there are three mayor reasons for the abuse of GCs in SLE: 1. the induction of GC therapy is not driven by a clear indication which allows reducing and stopping GCs again when the problem is solved; 2. GCs are given in patients with doubtful diagnosis and indications, then continuously increased because of incomplete response and extended endless instead of trying to find the right diagnosis and 3. the fear to stop GCs completely, which is maintained by limited individual experiences. These three reasons have to be addressed in every case at every time to taper GCs significantly. <h3>Disclosure of Interest</h3> M. Schneider Grant/research support from: GSK, UCB, Consultant for: Astra-Zeneca, GSK, Lilly, UCB, Speakers bureau: Astra-Zeneca, GSK, UCB
OC-025 Endoclot polysaccharide haemostatic system to reduce delayed bleeding following upper and lower gastrointestinal resection – preliminary results of the haemostop study
Authors: FJQ Chedgy, R Bhattacharyya, K Kandiah, A Kumar, P Bhandari
Journal: Gut (2015)

<h3>Introduction</h3> Endoscopic resection of advanced neoplasia in the upper and lower gastrointestinal tract is now possible with the techniques of endoscopic submucosal dissection (ESD) and endoscopic mucosal resection (EMR). However, these techniques create large mucosal defects, subsequently increasing the risk of significant post-procedural bleeding with catastrophic consequences. Endoclot<sup>TM</sup>is a topical hemostatic powder that rapidly absorbs water creating a high concentration of platelets, red blood cells and clotting factors – accelerating the natural coagulation cascade. Routine application of Endoclot<sup>TM</sup>to ESD or EMR defects is hypothesised to reduce the risk of significant post EMR/ESD bleeding. <h3>Method</h3> Prophylactic use of Endoclot<sup>TM</sup>,following endoscopic resection of large lesions, to prevent delayed bleeding was introduced in June 2014. <h3>Results</h3> <b>Group A (pre-Endoclot<sup>TM</sup>era):</b>496 patients, with polyps &gt;20 mm, underwent lower gastrointestinal EMR/ESD at our institution between 2005 and 2013 with a mean polyp size of 43 mm and 12% with scarring. Significant delayed bleeding was seen in 21 of 496 patients (4%). 264 patients underwent upper gastrointestinal EMR/ESD at our institution between 2005 and 2013. Significant delayed bleeding was seen in 9 of 264 patients (3%). <b>Group B (Endoclot<sup>TM</sup>group): </b>All patients undergoing endoscopic resection since June 2014 have had Endoclot<sup>TM</sup>sprayed onto the resection base. To date, 37 patients have undergone colonic EMR/ESD (mean polyp size 42 mm, 43% scarred) and 30 patients have undergone upper gastrointestinal resection. There was 1 significant delayed bleed in the colonic group (3%) requiring further endoscopic therapy. This patient had inadequate coverage (30%) of Endoclot<sup>TM</sup>due to device clogging, experienced early in the use of Endoclot<sup>TM</sup>. There were 2 (7%) bleeds in the upper GI group, which were managed with further endoscopic therapy without the need for blood transfusion. There have been no complications related to Endoclot<sup>TM</sup>use. <h3>Conclusion</h3> Endoclot<sup>TM</sup>shows promise in reducing the risks of delayed bleeding following endoscopic resection of neoplastic lesions from the gastrointestinal tract. Although our study group is small, we have demonstrated a 1% reduction in risk of delayed bleeding following EMR/ESD for large colonic polyps in a group with a significantly higher rate of scarring and therefore bleeding risk. A randomised controlled trial is required to clarify the role of routine use of Endoclot<sup>TM</sup>following EMR/ESD. <h3>Disclosure of interest</h3> None Declared.
OC-013 Genetic susceptibility to orofacial granulomatosis
Authors: R Goel, S Nayee, M Escudier, J Satsangi, J Mansfield, C Mathew, N Prescott, J Sanderson
Journal: Gut (2015)

<h3>Introduction</h3> Orofacial granulomatosis (OFG) is a rare, disfiguring inflammatory disorder of the mouth where a proportion of cases also have intestinal Crohn’s disease (CD). The aetiology remains largely unknown, although there is high prevalence of allergy in OFG with and without CD. Our objective was to investigate whether OFG and CD have shared genetic aetiology or whether OFG is mediated by distinct immune-related genetic susceptibility variants. <h3>Method</h3> Patients were clinically assessed and determined to either demonstrate isolated oral manifestations (OFG only) or concurrent intestinal CD (CD/OFG). Genomic DNA from 263 patients was genotyped using the Immunochip, a custom Illumina microarray assessing 196,524 genetic variants across multiple immune-related disease loci. Patient data was compared to data for 4,307 population controls from the UKIBD consortium. Statistical analysis was performed using PLINK, a whole genome association analysis program and the R statistical package. <h3>Results</h3> Analyses revealed two significant associations (p &lt; 2 × 10<sup>–6</sup>) within the OFG only cohort with single nucleotide polymorphisms (SNPs) on chromosome 11q13.5 near the <i>LRRC32</i>gene (p = 1.6 × 10<sup>–9</sup>) and on chromosome 6 (p = 3.9 × 10<sup>–7</sup>) within the MHC class I region. The 11q13.5 locus has previously shown association with atopic conditions and the MHC class I region is implicated in numerous allergic and autoimmune diseases, including CD. In addition, a highly suggestive association was detected from the CD/OFG group on chromosome 5p13 (p = 2.5 × 10<sup>–6</sup>), a known risk locus for CD. Collectively, these results suggest that OFG is influenced by common variants implicated in allergy and immunity, supporting the link between OFG and allergy. However there may also be some overlap with genetic aetiology for CD. Replication in a larger independent cohort is required to substantiate our findings. <h3>Conclusion</h3> OFG is likely to be a complex disease mediated by diverse genetic variants, sharing genetic susceptibility with allergic disorders and autoimmune conditions such as CD. <h3>Disclosure of interest</h3> None Declared.